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1. Introduction 
The microorganisms referred as mycoplasmas ("mushroom form") are eubacteria included 
within the Class Mollicutes (from latin mollis ="soft”, cutis= “skin"), which comprises the 
smallest self-replicating bacteria, showing distinctive features such as: a) lack of a rigid cell 
wall envelope, b) sterol incorporation into their own plasma membrane, and c) Reduced 
cellular (0.3 - 0.8 m diameter) and genome sizes (0.58-2.20 Mb). Some genera use the UGA  
stop codon to encode tryptophan [Bove, 1993; Razin et al., 1998].  
The term “mycoplasmas” will be used herein when referring to any species within the Class 
Mollicutes. Due to their reduced genome sizes, the mycoplasmas exhibit restricted metabolic 
and physiological pathways for replication and survival [Razin et al., 1998]. This makes 
evident why these bacteria display strict dependence to their hosts for acquisition of 
aminoacids, nucleotides, lipids and sterols as biosynthetic precursors. [Baseman & Tully, 
1997; Razin et al., 1998].  
Recognized human pathogenic mycoplasma species mostly belongs to the Mycoplasma and 
Ureaplasma genera (Table 1). Acute or fulminant diseases are rarely caused by these bacteria, 
instead they produce subclinical or covert infections that become chronic and/or persistent 
[Baseman & Tully, 1997; Razin et al., 1998]. Cell surface colonization and in some cases 
subsequent invasion and intracellular residence have been well documented for several 
Mycoplasma species which infect humans [Andreev et al., 1995; Baseman et al., 1995; Díaz-
García et al., 2006; Giron et al., 1996; Jensen et al., 1994; Lo et al., 1993; Taylor-Robinson et al., 
1991]. 
The primary habitats of the mycoplasmas infecting humans are the mucosal surfaces of the 
respiratory and genitourinary tracts [Cassell et al., 1994a; Taylor-Robinson, 1996]. Moreover, 
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the mycoplasmas display host- and tissue-specific tropism, reflecting their nutritional 
demands and parasitic lifestyle [Razin et al., 1998].  Thus, M. pneumoniae is found principally 
in the respiratory tract, whereas M. genitalium, Ureaplasma spp., M. hominis, M. fermentans 
and M. penetrans are primarily urogenital residents, but exceptionally they can be isolated 
from other unusual tissues and organs, especially in immunocompromised patients or in 
patients undergoing solid organ transplantation [Waites & Talkington, 2004; Waites et al., 
2005; Waites,  2008].  
Mycoplasmal respiratory infections in humans can be ascribed mainly to M. pneumoniae and, 
in fetuses or newborns, to Ureaplasma species. M. pneumoniae is a well-known pathogen in 
atypical and community-acquired pneumonia, whereas U. urealyticum and U. parvum have 
been associated with vertically-transmitted intrauterine and neonatal pneumonia [Taylor-
Robinson, 1996; Waites et al., 2005].  
 
Species 
Primary colonization sites Substrate utilization 
Oropharyngeal 
tract 
Urogenital 
tract 
Glucose Arginine Urea 
Mycoplasma 
fermentans 
     
M. genitalium      
M. hominis      
M. penetrans      
M. pneumoniae      
Ureaplasma parvum      
U. urealyticum      
 Present;  Absent 
Modified from Taylor-Robinson, 1996. 
Table 1. Mycoplasma species pathogenic for humans. 
A worldwide rise in the frequency of M. pneumoniae-associated lower respiratory tract 
disease has been observed, from 6 - >30% in the 1990s, to 0 - 66.7% in 2010 [Reviewed by 
Loens et al., 2003, 2010]. Therefore the pathogenic role of M. pneumoniae in respiratory 
disease has been proved in persons of all ages, sometimes causing severe respiratory 
disease, and it may induce clinically significant manifestations in extrapulmonary sites by 
direct invasion and/or immunologic effects. Only in the USA, M. pneumoniae is responsible 
for more than 100,000 hospitalizations of adults each year [Waites & Talkington, 2004; 
Waites, 2008]. This close interplay between M. pneumoniae and the host's respiratory 
epithelium induces local damage and in turn elicits release of inflammatory mediators by 
the host. The magnitude of the later response appears to be related to the severity of disease 
[Waites, 2008].  
Respiratory tract colonization with Ureaplasma spp., and rarely with M. hominis, in preterm 
infants has been associated with higher incidence of pneumonia, severe respiratory failure, 
bronchopulmonary dysplasia, and ultimately with death [Viscardi et al., 2002]. These 
bacteria can be transmitted from infected females to their fetus or newborn by three main 
different routes: a) Ascending intrauterine infection from vaginal colonization; b) 
Hematogenous spreading from placental infection,  and c) Acquisition of the microorganism 
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by the neonate during passage through an infected maternal birth canal. [Viscardi et al., 
2002; Waites et al., 2005]. An inverse correlation between ureaplasmal vertical transmission 
rate and gestational age has been established, and this increases with duration of premature 
rupture of membranes. Improved molecular detection of colonizing Ureaplasma in 
respiratory tract specimens suggests a higher frequency of colonization in very low birth 
weight infants than that previously reported with culture-based studies (25–48% vs. 20%) 
[Viscardi & Hasday, 2009]. 
Infrequently, M. fermentans has been detected in adults who developed respiratory distress 
syndrome and/or from bronchoalveolar lavage in AIDS patients with pneumonia, 
highlighting the potential of this species to cause lower respiratory tract disease in 
susceptible hosts [Waites &Talkington, 2004]. 
2. Taxonomic characterization of Mollicutes 
Modern mycoplasmal taxonomy relies on combined data from phenotypic traits and 
phylogeny based on the 16S rRNA gene sequences [Brown et al., 2007; International 
Committee on Systematics of Prokaryotes- Subcommittee on the taxonomy of Mollicutes 
(ICSP-STM), 2010]. Among the phenotypic characteristics, there are few useful metabolic 
markers including the ability to ferment glucose, the ability to hydrolyze urea and arginine, 
and dependence on cholesterol for growth and anaerobiosis. Despite the high rate of surface 
antigenic variation, serologic relatedness at the species level is still used in routine 
identification of mycoplasmas [Brown et al., 2007; ICSP-STM, 2010; Razin et al., 1998]. There 
are currently more than 200 species allocated into four orders, five families and eight genera 
within the class Mollicutes (Figure1), including the undefined candidatus Phytoplasma [Brown 
et al., 2007; ICSP-STM, 2010]. 
2.1 Phylogeny, genome content and molecular analysis 
The Mollicutes 16S rRNA-based phylogenetic tree is monophyletic arising from a single 
branch of the Clostridium ramosum branch. The Mollicutes split into two major branches: the 
AAP branch, containing the Acholeplasma, Anaeroplasma and Asteroleplasma genera, and the 
Candidatus Phytoplasma phyla; the other is the SEM branch that includes the Spiroplasma, 
Entomoplasma, Mesoplasma, Ureaplasma and Mycoplasma genera [Johansson et al., 1998; 
Maniloff  1992; Razin et al., 1998). Interestingly, the genus Mycoplasma is polyphyletic, with 
species clustering within the Spiroplasma, Pneumoniae and Hominis phylogenetic groups 
[Behbahani et al., 1993; Johansson et al., 1998; Maniloff 1992]. Nevertheless, additional 
phylogenetic markers such as the elongation factor EF-Tu (tuf) gene, ribosomal protein 
genes, the 16S/23S rRNA intergenic sequences, etc, have been already used as 
complementary comparative data, thus there is no unique phylogenetic tree for Mollicutes 
[Razin et al., 1998].  
The mycoplasmas may have evolved through regressive evolution from closely related 
Gram positive bacteria with low content of guanine plus cytosine (G+C), probably the 
Clostridia or Erysipelothrix [Bove, 1993; Brown et al., 2007; Razin et al., 1998]. The massive 
gene losses (i.e. genes involved in cell wall and aminoacid biosynthesis) had left 
mycoplasmas with a coding repertoire of 500 to 2000 genes [Sirand-Pugnet et al., 2007]. The 
G+C content in DNA of mycoplasmas varies from 23 to 40 mol%, while genome size range 
is 580–2200 Kbp, much smaller than those of most walled bacteria [Razin et al., 1998].  
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* Includes more than one hundred species. At present five species are recognized human pathogens. 
** Includes seven species, two of them are pathogenic for humans. 
Adapted from: Razin et al, 1998. 
Fig. 1. Taxonomy of Class Mollicutes.  
From a comparative analysis of the complete genome sequences from 17 mycoplasma species, 
Sirand-Pugnet et al., 2007, identified 729 clusters of orthologous groups of proteins (COGs) that 
represent 21 categories of diverse cellular functions. This analysis revealed that mycoplasmas 
shared a limited core genome (i.e. the essential translation machinery), while there is a wide 
diversity of COGs that are only found in one or a few species. Moreover, frequent chromosomal 
rearrangements occurring at specific loci involved in expression of surface proteins were also 
identified [Momynaliev & Govorun, 2001; Sirand-Pugnet et al., 2007]. 
3. Immune response  
Host defense in respiratory mycoplasmosis is dependent on both innate and humoral 
immunity. In general terms, mycoplasmas reaching the lower respiratory tract may be 
opsonized by antibody and complement, and then activated macrophages begin 
phagocytosis and migration to the site of infection by chemotaxis. Finally, complement-
mediated cytolysis may then play a role in limiting the growth of the mycoplasmas. 
However, immunity against mycoplasmal infection is typically short-lived, hence infection 
recurrence is common (Waites et al., 2007, 2008). 
3.1 Innate and adaptive immune response 
M. pneumoniae infection is able to activate the host innate immune system, so the 
inflammatory event elicited by accounts for the early signs and symptoms of the infection.  
After become opsonized, M. pneumoniae is susceptible to complement-mediated cytolysis, 
probably through both the alternative and classical pathways [Waites et al., 2007].  It has 
been suggested that innate immune recognition of M. pneumoniae has also a pivotal role for 
mucin expression in the airway, at both mRNA and protein levels, since blockage of the toll-
like receptor (TLR)-2 signaling pathway results in marked reduction of mucin expression 
[Chu et al., 2005]. Moreover, M. pneumoniae is capable of interact with mast cells and 
surfactant protein (SP)-A, resulting in cytokine production and bacterial growth inhibition, 
respectively [Waites et al, 2007].  
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After primary encounter with M. pneumoniae, the immune system of an immunocompetent 
host responds by rapidly producing antibodies (mainly directed against the P1 adhesin and 
glycolipid antigens) that peak after 3 to 6 weeks, followed by a gradual decline over months to 
years [Waites & Talkington, 2004]. The onset of symptoms may coincide with demonstrable 
antibody titers due to prolonged incubation period. Acute infection can often be difficult 
observed by evidence of rising M. pneumoniae-specific IgM antibodies, especially in pediatric 
populations. [Waites, 2007, 2008]. IgA antibodies are produced early in the course of disease, 
rise quickly to peak levels, and decrease earlier than IgM or IgG [Waites & Talkington, 2004]. 
Adaptive immunity, characterized by both B and T lymphocyte responses, has a major 
impact on the progression of M. pneumoniae respiratory disease. Mycoplasmas activate the 
immune system by inducing non-specific proliferation of B- and T-lymphocyte populations 
(mitogenic stimulation), thereby inducing autoimmune responses with concurrent 
production of cytokines (Table 2). Immune responses that develop after infection often fail  
 
Organism Cells / Experimental system Cytokine(s) released 
M. 
pneumoniae 
 Lung Alveolar type II pneumocytes 
 
 
 Nasal epithelial cells/peripheral 
blood macrophages 
 
 
 
 
 Peripheral blood mononuclear cells 
 
 
 Lung ephitelial carcinoma A549 
cells 
 M. pneumoniae-infected patients 
Interleukin (IL)-1ǃ, tumour 
necrosis factor (TNF)-ǂ, IL-8.  
 
IL-2, IL-6, RANTES, 
intercellular adhesion 
molecule (ICAM)-1, 
transforming growth factor 
(TGF)-ǃ1 and TNF-ǂ 
 
IL-1ǃ, IL-2/IL-2R, IL-6, 
Interferon (IF)-Ǆ, and TNF-ǂ. 
 
IL-1ǃ, IL-8, and TNF-ǂ. 
 
IL-2/IL-2R, IL-4, IL-5, IL-6, 
IL-8, IL-12, IL-18, IF-Ǆ, and 
TNF-ǂ. 
Ureaplasma 
spp. 
 Neonatal fibroblasts 
 
 Peripheral blood/Cord blood 
monocytes 
 
 THP-1-derived macrophages / 
Human lung fibroblasts 
 
 
 THP-1 monocytes 
IL-6 and IL-8. 
 
TNF-ǂ, IL-8, IL-6, and IL-10. 
 
 
TNF-ǂ, IL-6, ICAM-1, and 
vascular endothelial growth 
factor (VEGF).  
 
IL-1ǂ, TNF-ǂ, and IL-8. 
Data from Dakhama et al., 2003; Kazachkov et al., 2002;  Li et al., 2000a; Manimtim et al., 2001; Peltier et 
al., 2008 ; Stancombe et al., 1993; Yang et al, 2004. 
Table 2. Mycoplasma-induced cytokine secretion.  
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to eliminate the mycoplasma, indicating that adaptive immunity apparently has a limited 
effect on clearance of an established infection, thus leading to asymptomatic carriage for 
variable periods of time. Cytokine production and lymphocyte activation may either 
minimize disease through the enhancement of host defense mechanisms and subsequent 
elimination of the infecting organisms, or exacerbate disease through the development of 
immunologic hypersensitivity [Waites et al, 2007, 2008]. It has been suggested that there is 
no correlation between severity of pneumonia caused by M. pneumoniae and T-cell 
deficiencies, thus cell-mediated defense against respiratory mycoplasmosis appears to be 
rather limited [Cartner et al, 1998]. 
Molecular mimicry, survival within cells and phenotypic plasticity (antigenic variation) are 
the major mechanisms by which mycoplasmas evade the immune response [Chambaud et 
al, 1999; Razin et al., 1998; Rottem & Naot, 1998]. Furthermore, a transient impairment of T-
lymphocyte function, or depletion of CD4+ T cells, can be induced by M. pneumoniae [Waites 
et al., 2007].  
In the context of perinatal pneumonia, very low birth weight infants have relative 
deficiencies in mucosal barrier function and in both the innate and adaptive immune 
responses. These immature hosts may generate poor immune responses, including secretory 
IgA, serum complement components, defensins, fibronectin, and altered cytokine 
production. Impaired chemotaxis, phagocytosis, and microbial killing by neonatal immune 
cells highlight the vulnerability of preterm neonates to systemic infections, and partially 
explain the eventual systemic spread of bacteria [Waites et al., 2005]. 
3.2 Cell culture models 
Mycoplasmas possess an impressive capability of maintaining a dynamic surface 
architecture that is antigenically and functionally versatile, contributing to their capability to 
adapt to a large range of habitats and cause diseases that are often chronic in nature 
[Rottem, 2003]. The probable role of mycoplasmas in chronic respiratory diseases has been 
studied in vitro using diverse cell culture models. Several of these models are focusing in the 
study of adherence, invasion and fusion as the strategies to induce damage to the host cells 
[Baseman et al., 1995; Razin, 1999; Rottem, 2003].  
M. pneumoniae is the most extensively studied system with respect to adhesions and 
receptors [Rottem, 2003] because of its significance as pathogen for humans. Models in 
human lung cells analyzed by inmunofluorescence and confocal microscopy reveal that M. 
pneumoniae parasitize cells surface, enter the intracellular spaces and locate throughout the 
cytoplasmic and perinuclear regions within 2 hr postinfection [Baseman et al., 1995]. The 
microorganism can survive within the host cells for prolonged periods of time, well 
protected from the immune system and from de action of many antibiotics and may explain 
its pathogenic potential [Yavlovich et al., 2004]. Another in vitro studies show that this 
microorganism has a polar, tapered cell extension at one of the poles containing an electron-
dense core in the cytoplasma. This structure, termed the tip organelle, functions both as an 
attachment organelle and as the leading end in gliding motility [Baseman et al., 1995; Razin, 
1999; Rottem, 2003; Svenstrup et al., 2002]. Host-pathogen studies in an air-liquid culture of 
differentiated human airway epithelial cells revealed that the microorganism bounds 
initially to ciliated epithelial cells, but colonization become more evently distributed over 
the entire surface with time [Krunkosky et al., 2007]. We recently studied the adherence of 
U. urealyticum to a respiratory epithelial cell line, as a virulence factor for lung disease. We 
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describe that U. urealyticum induce changes in cell morphology mediated probably by the 
loss of microvilli, and that the microorganism invades the cell forming vacuoles [Torres-
Morquecho et al., 2010]. 
Since chronic lung disease is characterized by an early increased number of activated 
neutrophils and alveolar macrophages, with later architectural epithelial and endothelial cell 
damage [Li et al., 2002], all of these cells represent excellent targets for the study of 
mycoplasmal infections. As the key processes occurring in all respiratory diseases are the 
exacerbation of lung inflammation and injury, most of the in vitro models have been 
developed to study the inflammatory response mediated primarily by cytokines.  
Different studies have demonstrated that the release of Interleukin (IL)-2, IL-6 RANTES, 
ICAM-1, TGF-ǃ1 and TNF- by human nasal epithelial cells and peripheral monocytes 
infected with M. pneumoniae could be implicated in the asthma exacerbation in children and 
may play a role in the pathogenesis of chronic asthma [Dakhama et al., 2003; Kazachkov et 
al., 2002; Krunkosky et al., 2007]. Additionally, it has been recently demonstrated that M. 
pneumoniae infection induces reactive oxygen species and DNA damage in human lung cells 
[Sun et al., 2008]. 
A number of studies show that Ureaplasma urealyticum induce the production of TNF-ǂ, IL-8, 
IL-6 [Li et al., 2000a; Manimtim et al., 2001; Peltier et al., 2008], NF-B and nitric oxide [Li et 
al., 2000b] by human macrophages and monocytes. Infection assays in macrophages 
performed in combination with LPS showed that U. urealyticum enhances the 
proinflammatory response to a second infection by blocking expression of 
counterregulatory cytokines (IL-6 and IL-10), predisposing the preterm infant to prolonged 
and dysregulated inflammation, lung injury, and impaired clearance of secondary infections 
[Manimtim et al., 2001]. Furthermore, U. urealyticum stimulates macrophages to produce 
vascular endothelial grow factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) in 
vitro, which are potentially associated with both early and later pathological changes in the 
lung during the development of chronic lung disease [Li et al., 2002a]. The same raise in 
proinflammatory cytokine release is observed when U. urealyticum interacts with neonatal 
pulmonary fibroblast [Stancombe et al., 1993], suggesting a role in the development of 
bronchopulmonary dysplasia. Finally, it has been demonstrated that U. urealyticum induces 
apoptosis in human lung epithelial cells and macrophages [Li et al., 2002b], involving in 
impairing lung structure observed in chronic lung disease.  
4. Lung disease in humans 
4.1 Mycoplasma pneumoniae  
Respiratory infections due to M. pneumoniae can affect either the upper or the lower tract, or 
both simultaneously. This pathogen is responsible for up to 40% of cases of community-
acquired pneumonia [Atkinson, et al., 2008]. Nearly 50% of the M. pneumoniae-infected 
patients show non-specific signs and symptoms, often similar to those produced by other 
respiratory pathogens such as Chlamydophila pneumoniae, Streptococcus pneumoniae and some 
viruses, and although these infections are usually mild or  asymptomatic, they are not 
always self-limiting [Waites & Talkington, 2004; Waites et al.,  2008]. 
Symptomatic disease emerges gradually within few days post-infection and persists for 
several weeks or months. Upper respiratory tract symptoms include sore throat, fever, 
cough, headache, coryza, myalgias, chills, earache and malaise. Clinical manifestations of 
lower respiratory tract infections generally include: non-productive cough which later turns 
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productive with non-hemorrhagic sputum, dyspnoea, adenopathy, wheezing and, rarely, 
respiratory failure [Waites & Talkington, 2004; Waites et al., 2008]. 
4.1.1 Pathogenesis 
Occurrence of airway disease initiates from the close interplay between the microorganism 
and the mucosal epithelium as a result of cytadherence, the main virulence factor of the 
bacterium, which is mediated through a polarized tip attachment organelle. This tip 
structure comprise the main protein adhesin, named P1, along with several other adhesins 
and accessory proteins (High Molecular Weight  [HMW]-1, HMW-2,  HMW-3, Protein [P]-
90, P-40 and P-30) [Waites et al., 2008].  
Unlike other bacterial lung pathogens (S. pneumoniae, Pseudomonas aeruginosa and 
Haemophilus influenzae) which bind specifically to glycolipids containing unsubstituted  
GalNAcǃ1-4Gal residues, M pneumoniae attaches to host cells either through a sialic acid-free 
glycoprotein or sulfated glycolipids containing terminal Gal(3SO4)_1 residues. It is worthy 
to note that the apical microvillar border and cilia of the epithelium express the 
sialoglycoconjugate-type receptors, thus allowing the selective attachment of M. pneumoniae 
to the ciliated cells [Krivan et al., 1988, 1989; Roberts, D.D. et al, 1989; Olson & Gilbert, 1993; 
Rottem & Naot, 1998]. 
Cytadhered M. pneumoniae is able to cause damage through generation of reactive oxygen 
species (ROS), which act in concert with host’s endogenous ROS to induce oxidative stress. 
Bacteria-derived superoxide anions act to inhibit catalase in host cells, thereby reducing the 
enzymatic breakdown of peroxides, rendering the host cell more susceptible to oxidative 
damage [Rottem & Naot, 1998; Waites et al., 2004]. Mycoplasmal species exert primarily 
deleterious effects on the host respiratory epithelium, such as ciliostasis and apoptosis, 
resulting in localized damage and an immune response which, although often robust, is 
poorly efficacious in terms of clearing the organism or preventing subsequent reinfections 
[Waites et al., 2004]. 
Recently, a M. pneumoniae protein homolog to the pertussis toxin S1 subunit was identified 
and it showed specific binding to surfactant protein A [Kannan et al., 2005] This protein also 
showed protein:ADPribosyltransferase activity, inducing vacuolation and ciliostasis in 
cultured host cells. This immunodominant protein has been named as community-acquired 
respiratory distress syndrome toxin (CARDS TX). Host-cell targets for CARDS TX remain 
unidentified at present, as does how the toxin's function might relate to its specific binding 
to surfactant protein A [Kannann & Baseman, 2006; Waites et al., 2004, 2008].  
Cytopathic effects observed in M. pneumoniae-infected host cells include loss of ciliated 
epithelia, cell vacuolation, reduced oxygen consumption, reduced glucose utilization, 
diminished amino acid uptake and macromolecular synthesis, ultimately leading to 
exfoliation. Clinically, the above mentioned events in the lung tissues are noticeable by the 
persistent hacking cough [Waites et al., 2004, 2008].  
Some clinical characteristics of M. pneumoniae infections are consistent with an intracellular 
location of the pathogen, mainly the establishment of latent or chronic infections, limited 
efficacy of some antimicrobials, necessity for prolonged treatment to eradicate infection in 
some instances and circumvention of the host immune response [Waites & Talkington, 2004] 
4.1.2 Role in COPD and asthma 
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lungs 
that leads to blockage of the airways which eventually interferes with the exchange of 
www.intechopen.com
Current Status of the Mollicute (Mycoplasma) Lung Disease:  
Pathogenesis, Diagnostics, Treatment and Prevention 
 
339 
oxygen and carbon dioxide, making breathing progressively more difficult. It is mainly 
associated with long-term smoking, but presence of persistent bacterial infections has been 
related to the etiology, pathogenesis and clinical course of COPD [Blasi, 2004; Sethi, 2000].  
Well-known bacterial pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, 
and Moraxella catarrhalis have been associated with acute exacerbations in COPD and 
asthma. [Guilbert & Denlinger, 2010; Sethi, 2000; Waites & Talkington, 2004]. Since late 
1970’s, several authors suggested a relationship between COPD and M. pneumoniae infection 
[Buscho et al., 1978; Gump et al., 1976; Smith et al., 1980], but it was until late 1990’s and early 
2000’s that several studies based on serology brought attention once more on this issue. 
[Lieberman et al., 2001, 2002; Mogulkoc et al., 1999]. It is well known that mycoplasmas 
species pathogenic for humans have the ability to induce chronic disease states in which 
clearance of the bacteria is extremely difficult. [Rottem & Naot, 1998].  
A growing body of evidence indicates that there is a link between M pneumoniae infection 
and COPD. In a Yemeni study, M. pneumoniae infection was demonstrated by culture and 
serologic methods in 20.4% (11/54) of COPD patients [Al-Moyed & Al-Shamahy, 2003]. In a 
group of 144 Dutch patients with CAP, 12.5 % were infected with M. pneumoniae and less 
than 40% of these M. pneumoniae-infected patients had COPD, even though specific 
serologic tests were mainly negative [Dorigo-Zetsma et al., 2001]. In contrast. M. pneumoniae 
was the most frequent pathogen (22.7%, alone or in association with other microorganisms) 
among CAP patients that required hospitalization related to COPD, asthma and/or 
pulmonary fibrosis. [Caberlotto et al., 2003].  
A rather weak association between M. pneumoniae infection and acute asthma has been 
suggested on the basis of contradictory data about mycoplasma infection frequencies from 
several trials. Conversely, strong associations of this pathogen with chronic asthma have 
been established [Guilbert & Denlinger, 2010; Sutherland & Martin, 2007]. Evidence for this 
association includes the following: a) Higher prevalence of M. pneumoniae in asthmatics than 
in healthy subjects; b) Improved pulmonary function in mycoplasma-infected asthmatic 
patients after treatment with macrolide antibiotics; c) Demonstration of long-term airway 
dysfunction consistent with a persistent infection; and d) M. pneumoniae-induced production 
of inflammatory mediators (IgE, substance P and neurokinin 1, and IL-5) implicated in the 
pathogenesis of asthma [Waites & Talkington, 2004]. 
By means of murine models of chronic respiratory infection, it has been demonstrated M. 
pneumoniae can produce pneumonia, with consistent immunologic responses in term of 
specific IgM antibodies [Wubbel et al., 1998]. Other findings revealed post-infection time-
dependent differential cytokine production, with increased expression of TNF-ǂ, IL-1, IL-6, 
and IFN-Ǆ in the acute phase, whereas IL-2 and IL-2 receptor gene expression was seen only 
during reinfection. [Pietsch et al., 1994].  
Relationship between the timing of Mycoplasma infection, allergic sensitization, and 
subsequent pulmonary physiologic and immune response was assessed by Chu et al., 2003. 
Before ovalbumin sensitization, experimental M. pneumoniae infection resulted in reduced 
airway hyperresponsiveness (AHR), reduced lung inflammatory cell recruitment, and a 
predominantly Th1 response. In contrast, M. pneumoniae infection post-sensitization initially 
caused a transient reduction in AHR, followed by augmented AHR, and a Th2-dominant 
airway inflammatory process that potentiates organism survival in the lungs. Further 
characterization of the M. pneumoniae effects on ovoalbumin sensitized mice, long-term 
infection provoked collagen deposition in airway wall accompanied by augmented 
expression of TGF-ǃ1 in the lungs [Chu et al., 2005]. 
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4.2 Mycoplasmas in immunocompromised hosts 
Association between immunodeficiency and mycoplasmal infections has been reported 
since the mid 1970s to the date. Mycoplasmas can disseminate from localized infections and 
cause invasive diseases, especially in hypogammaglobulinemic subjects.  Significance of 
mycoplasma species other than M. pneumoniae or Ureaplasma spp. in respiratory diseases is a 
matter of controversy [Cassell et al., 1994a].  
4.2.1 Mycoplasma fermentans associated to lung diseases 
It has been well documented that M. pneumoniae produces respiratory disease in adults; it is 
also worthy of consideration as a cause of respiratory infections in persons of all age groups, 
though very few attempts have been made to determine whether it occurs in neonates and 
young infants [Waites et al., 2005]. However, due to their fastidious growth requirements 
and presumably less frequent occurrence than Ureaplasma spp. or M. hominis, much less is 
known about the epidemiology and disease associations of organisms such as M. fermentans, 
M. genitalium, and M. penetrans in humans. Waites and Talkington, 2005, recently reviewed 
the importance of M. fermentans in human diseases and provided more detail on the 
conditions described above as well as others [Waites et al., 2005]. 
The role of M. fermentans as a pathogen is unclear, it has been associated with the 
pathogenesis of rheumatoid arthritis [Williams et al., 1970]. However, the potential 
importance of M. fermentans in human diseases has recently been further demonstrated. 
Isolation of about 30 strains of M. fermentans from previously healthy non-AIDS patients 
who had a sudden onset of a severe and often fatal form of respiratory distress syndrome 
was recorded by R. Dular in Ottawa, Canada [unpublished, as cited by Hu et al., 1998]. Also 
they have reported the detection by PCR of Mycoplasma fermentans in the respiratory tract of 
children with pneumonia [Cassell et al., 1994b]. It has been demonstrated that a wild strain 
of M. fermentans isolated from the respiratory tract of an asthma patient was able to produce 
severe experimental respiratory disease in hamsters [Yáñez, 1997]. Román-Méndez et al., 
2007, have showed that Mycoplasma fermentans persisted in the respiratory tract of hamsters 
during 120 days and all hamsters developed histological evidence of pulmonary 
inflammation. Lo et al., 1993, have reported the presence of infections due to Mycoplasma 
fermentans in patients with adult respiratory distress syndrome with or without systemic 
disease. M. fermentans can be detected in the upper and lower urogenital and respiratory 
tracts and bone marrow, and has been associated with a variety of systemic conditions in 
adults including inflammatory arthritis and pneumonia [Ainsworth et al., 2000a, 2001; 
Gilroy et al., 2001;  Lo et al., 1989; Schaeverbeke et al.,1996; Taylor-Robinson, 1996; Tully, 
1993; Waites & Talkington, 2005]  
It has been recovered from the throats of 16% of children with community-acquired 
pneumonia, some of whom had no other etiologic agent identified, but the frequency of its 
occurrence in healthy children is not known. [Taylor-Robinson, 1996].  
M. fermentans has also been detected in adults with an acute influenza-like illness who 
developed respiratory distress syndrome, and from bronchoalveolar lavage in AIDS patients 
with pneumonia, sometimes as the sole microbe, so it clearly has the potential to cause 
respiratory tract disease in susceptible hosts [Lo et al., 1993; Ainsworth et al., 2001]. This 
mycoplasma is also known to colonize mucosal surfaces in healthy persons, complicating 
efforts to understand its role in disease [Ainsworth et al., 2000b].  
Mycoplasma fermentans, isolated decades ago from the urogenital tract, has been implicated 
in several disease conditions. Interest in this organism has recently increased because of its 
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possible role in the pathogenesis of rheumatoid arthritis. Over the last decade, intensive 
studies have been carried out in order to understand the strategy employed by M. fermentans 
to interact with host cells and to avoid or subvert host protective measures [Rechnitzer et al., 
2011]. 
Attention was focused on M. fermentans in the late 1980’s because of reports that it may be 
important as a mediator or cofactor in the development of AIDS [Lo et al., 1989; Saillard et 
al., 1990]. The identification of mycoplasmal membrane components that participate in the 
adhesion of the parasite and the finding that some mycoplasmas can reside intracellularly 
[Rottem, 2003] open up new horizons in the study of the role of mycoplasma and host 
surface molecules in mycoplasma–host cell interactions [Rechnitzer et al., 2011]. 
Unlike M. pneumoniae, M. fermentans lacks a well-defined terminal attachment tip to mediate 
attachment and cell invasion. Since intracellular organisms are resistant to host defense 
mechanisms and to antibiotic treatment, this feature may account for the difficulty in 
eradicating mycoplasmas from cell cultures. A study by Yavlovich et al., 2001, demonstrated 
that M. fermentans binds plasminogen and converts it to plasmin, where upon mycoplasmal 
cell surface proteins are altered to promote its internalization. The role of plasminogen 
activation as a virulence factor and other aspects of M. fermentans pathogenesis, including 
the importance of membrane surface proteins that mediate cell fusion, cytadherence, and 
antigenic variation, are discussed by Rottem, 2003. The fusion of M. fermentans with 
eukaryotic host cells raises exciting questions on how microinjection of mycoplasmal 
components into eukaryotic cells affects host cells [Rottem, 2003]. 
The fusion process as well as the invasion of host cells by M. fermentans brings up an 
emerging theme in mycoplasma research, the subversion by M. fermentans of host cell 
functions mainly in signal-transduction pathways and cytoskeletal organization [As cited by 
Rechnitzer et al., 2011].  
4.2.2 Mycoplasma penetrans, Mycoplasma pirium and Human Immunodeficiency 
Virus (HIV) disease 
M. penetrans was first isolated from urine of homosexual men infected with (HIV), but not 
from healthy age-matched subjects. Subsequent studies suggested an association of this 
mycoplasma with Kaposi's sarcoma, but later findings did not confirm such association. 
This organism has been detected in HIV-negative persons, and despite its ability to invade 
epithelial cell, there is no conclusive evidence of any significant role in human disease 
[Yañez et al., 1999; Waites et al, 2005; Baseman & Tully, 1997]. 
Initial isolation of M. pirum from human peripheral blood lymphoid cells of HIV-positive 
patients, along with M. penetrans and M. fermentans, lead scientists to suggest a role as 
cofactor in acquire immunodeficiency syndrome (AIDS) progression. However, despite M. 
pirum was detected in rectal specimens of homosexual men and in urine of patients with 
AIDS, no conclusive evidence of its pathogenic role in human disease has been found. 
[Waites et al, 2005; Baseman & Tully, 1997]. Taking into account that M. penetrans and M. 
pirum have been associated with immune compromise, extragenital dissemination in 
infected patients, including respiratory disease, should be considered. 
4.3 Ureaplasma urealyticum and Ureaplasma parvum in urogenital and respiratory 
tract infections 
Although U. urealyticum and U. parvum are common commensals of the urogenital tract of 
humans, they are considered as important pathogens associated with infertility and non-
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gonococcal urethritis in men, multiple obstetrical complications in women, and neonatal 
lung disease [Viscardi, 2010; Volgmann et al., 2005; Waites et al., 2005).  
Genital ureaplasmas are natural residents of male urethra contaminating the semen during 
ejaculation. However, these microorganisms, particularly U. urealyticum, play and etiologic 
role in both genital infections and male infertility (Gdoura et al., 2008). Recent studies reveal 
that U. urealyticum strains are isolated more often in men with non-gonococcal urethritis 
than in healthy men (Deguchi et al., 2004; Maeda et al., 2004; Povlsen et al., 2002). 
Ureaplasmas are widespread among the male partners of infertile couples (Gdoura et al., 
2007, 2008), and their presence is correlated with the alteration of some characteristics of 
semen, such as density, sperm motility, concentration, and probably morphology (Naessens 
et al., 1986; Reichart et al., 2000; Wang et al., 2006). The attachment to sperm and the 
induction of germ cell apoptosis have been proposed as mechanisms by which U. 
urealyticum affects sperm quality (Shang et al., 1999; Waites et al., 2005). 
The infection of the female urinary tract with U. urealyticum is frequently overlooked. 
However, since a high isolation rate of this microorganism has been observed in urine and 
urethral samples from women with unexplained chronic urinary symptoms, treatment of 
the infection is now indicated (Baka et al., 2009; Potts et al., 2000).  
Genital ureaplasmas can be found in vaginal flora in 40% of sexually inactive and 67% 
sexually active women (Viscardi, 2010). The infection is generally asymptomatic in nature, 
and is sexually transmitted between partners. Ureaplasmas can survive in the reproductive 
tract for many years, undetected, until the patient is specifically tested for the infection.  
U. urealyticum is recovered from the lower genital tract of 70-80% of pregnant women (Carey 
et al., 1991; Volgmann, 2005), but vaginal carriage is not reliably predictive of preterm birth 
(Kafetzis et al., 2004; Povlsen et al., 2001). However, there is a consistent association when 
the infection is present in the amniotic fluid, chorioamnion or placenta (Eschenbach, 1993; 
Kundsin et al., 1996; Yoon et al., 2000, 2003). The secretion of phospholipases A and C has 
been suggested to be the means by which ureaplasmas may initiate preterm labor by 
liberating arachidonic acid and altering prostaglandin synthesis (De Silva & Quinn, 1986). In 
addition, recently we reported that the interaction between U. urealyticum, intrauterine 
leukocytes and fetal membranes results in the secretion of high amounts of IL-1b and 
prostaglandin E2, which could induce uterine contraction leading to preterm labor (Estrada 
et al., 2010). Isolation of U. urealyticum from chorioamnion has been consistently associated 
with histological chorioamnionitis and is inversely related to birth weight, even when 
adjusting for duration of labor, rupture of the fetal membranes, and the presence of other 
bacteria [Cassel et al., 1993; Waites et al., 2005]. 
There is accumulating epidemiologic and experimental evidence that intrauterine or 
postnatal infection with genital ureaplasmas is a significant risk factor for complications of 
extreme preterm birth such as bronchopulmonary dysplasia (BDP) and intraventricular 
hemorrhage [Kafetzis, et al., 2004; Viscardi, 2010].  Ureaplasma spp can be transmitted from 
an infected mother to the fetus or neonate by ascending intrauterine infection, 
hematogenous route involving umbilical vessels, or through passage of an infected maternal 
birth canal with resultant colonization of the skin, mucosal membranes or respiratory tract 
[Waites, 2005]. 
Among premature infants, respiratory tract colonization with genital ureaplasmas has been 
associated with pneumonia, chronic lung disease, infant wheezing, respiratory distress 
syndrome, acute respiratory insufficiency, and increased mortality [Cultrera et al., 2006; 
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Kafetzis et al., 2004]. For some infants, ureaplasmal infection triggers a vigorous response in 
the lungs involving the elevation of adhesion molecules, collagenases, proinflammatory 
cytokines and neutrophil activation and migration, which increase the risk of developing 
bronchopulmonary dysplasia characterized by delayed alveolarization, chronic 
inflammation, and fibrosis [Manimtim et al., 2001; Schelonka & Waites, 2007]. Additionally, 
free radical generation and oxidative injury induced by recruited neutrophils could 
contribute to lung damage [Buss et al., 2003]. Apoptosis of pneumocytes and pulmonary 
mesenchymal cells has been shown to occur as part of the pathogenesis of U. urealyticum [Li 
et al., 2002], while U. parvum lipoproteins activate NF-kB and induce TNF- in 
macrophages, favoring the inflammatory response (Shimizu et al., 2008). Apparently, there 
is no trend in the prevalence of either species between infants with or without 
bronchopulmonary dysplasia [Katz et al., 2005]. 
5. Diagnostic procedures  
Much of the mycoplasmal respiratory diseases, especially those caused by M. pneumoniae, 
are underdiagnosed because the laboratory diagnostic strategies are quite different than 
those for fast-growing bacteria. It is noteworthy that mycoplasmal etiology of respiratory 
diseases is considered only after failure of diagnosis of other common bacterial etiologies. In 
addition, there are few specialized or reference laboratories and skilled personnel [Cassell et 
al., 1994a; Waites et al., 2000]. 
5.1 Types of specimens, transport and collection 
Detection or isolation of mycoplasmas in clinical specimens requires careful consideration of 
the type of specimen available and the organism (species) sought [Cassell et al., 1994a]. 
Specimens appropriate for laboratory diagnosis of respiratory mycoplasmal infections 
include: Bronchoalveolar lavage (BAL), sputum, pleural fluid, nasopharyngeal and throat 
swabs, endotracheal aspirates (ETA) and lung biopsies. Liquid specimens or tissues do not 
require special transport media if culture can be performed within 1 hour, otherwise 
specimens should be placed in transport media, such as SP-4 broth, 10B broth or 2SP broth. 
When swabbing is required, aluminum- or plastic-shafted calcium alginate or dacron swabs 
should be used, taking care to obtain as many cells as possible [Atkinson et al., 2008; Cassell 
et al., 1994a; Waites et al., 2002]. 
Other specimens such as blood, cerebrospinal fluid, pericardial fluid and synovial fluid 
must be considered when extrapulmonary disease is suspected, thus specimen collection 
should reflect the site of infection and/or the disease process. [Atkinson et al., 2008; Waites 
& Talkington, 2004]. 
5.2 Culture 
Routine culture methods for isolation/detection of most mycoplasma species are time-
consuming, thus emission of results may delay up to 5-6 weeks. Furthermore, there is no 
ideal formulation of culture media for all pathogenic species, mainly due to their different 
substrate and pH requirements [Waites et al., 2000]. Modified SP-4 media (broth and agar) 
[Lo et al., 1993], containing both glucose and arginine, can support the growth of all human 
pathogenic Mycoplasma species, including the fastidious M. pneumoniae and M. genitalium.  A 
set of Shepard´s 10B broth and A8 agar can be used for cultivation of Ureaplasma species and 
M. hominis.   
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For cultivation, specimens in transport media should be thoroughly mixed, and then should 
be 10-fold serially diluted in broth (usually up to 10-6) in order to overcome potential 
inhibitory substances, and to allow semiquantitative estimation of mycoplasmal load. 
Subcultures in agar media should be also performed. [Cassell et al., 1994a]. All inoculated 
media are incubated under microaerophilic atmosphere at 37°C.   
Detection of M. pneumoniae in broth culture is based on its ability to ferment glucose, causing 
an acidic shift after 4 or more days, readily visualized by the presence of the phenol red pH 
indicator.  Broths with any color change, and subsequent blind broth passages, should be 
subcultured to SP4 agar, incubated, and examined under the low-power objective of the light 
microscope in order to look for development of typical “fried egg”-like colonies of up to 100 
µm in diameter (Figure 2). Examination of agar plates must be done on a daily basis during the 
first week, and thereafter every 3 to 4 days until completing 5 weeks or until growth is 
observed [Waites et al., 2000, 2004].  M. genitalium, M. fermentans and M. penetrans are also 
glucose-fermenting and formed colonies morphologically indistinguishable from those of M. 
pneumoniae, thus serologic-based definitive identification can be done by growth inhibition, 
metabolic inhibition, and mycoplamacidal tests [Cassel et al., 1993].  
 
 
A) Typical ”Fried-egg”  appearance of Mycoplasma spp. colonies on SP-4 agar. B) Dienes-stained 
mycoplasma colonies. C)  Tiny brown-colored ureaplasmal colonies on modified SP-4 agar. D) 
Macroscopic view of Dienes-stained mycoplasma colonies growth on SP-4 agar in 30 mm-diameter Petri 
dishes. E) Closer view of  an ureaplasma colony. 
Fig. 2. Morphology of mycoplasma colonies in culture. 
Hidrolysis of urea by Ureaplasma and hidrolysis of arginine by M. hominis cause an alkaline 
shift, turning the colour of 10B broth from yellow to pink. Tiny brown or black irregular 
colonies of Ureaplasma species develop between 1 -5 days on A8 agar plates, due to urease 
production in the presence of manganese sulfate (Figure 2). Typical fried egg colonies are 
produced by M. hominis in this medium [Cassell et al., 1994a, Waites et al., 2000]. 
5.3 Immunodiagnosis by serological tests 
As culture of M. pneumoniae is slow and insensitive, the laboratory diagnosis of M. 
pneumoniae infection has largely relied on serological testing. Seroconversion or rising 
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specific antibody titers are observed among M. pneumoniae-infected patients. This 
immunologic response can be measured by several tests, including: metabolic inhibition 
assay, complement fixation or enzyme-linked immunoassays (EIA). Serum samples are easy 
to collect and handle, but it is required paired acute- and convalescent-phase specimens. 
Commercial assay formats include indirect immunofluorescence, particle agglutination 
assay, and EIA [Atkinson et al., 2008, Cassell et al., 1994a; Waites & Talkington, 2004]. 
Prior to the widespread availability of commercialized antibody assays, presence of cold 
agglutinins ( IgM antibodies that are produced 1 to 2 weeks after initial infection in about 
half of M. pneumoniae-infected subjects) was used to confirm primary atypical pneumonia 
(Waites & Talkington, 2004). Although there have been recent improvements, the sensitivity 
and specificity of antibody detection is still suboptimal. Nevertheless, the complex and time-
consuming nature of many of the serological assays that have been used in the past have 
limited acceptance of serology for routine diagnostic testing. [Cassell et al., 1994a; Waites et 
al., 2000]. 
At present, besides research laboratories, no serologic tests assays for mycoplasmas other 
than M. pneumoniae have been standardized for diagnostic purposes in routine clinical 
microbiology laboratories nor made commercially available elsewhere. [Cassell et al., 1994a, 
Waites et al., 2005]. 
5.4 PCR and other molecular tests 
Nucleic acid amplification techniques (NAATs) are more sensitive, and considerably more 
rapid than culture, showing a fair to good correlation with serology.  PCR testing for 
species-specific mycoplasmal infection are suitable for both upper and lower respiratory 
samples. Interestingly, sample processing prior amplification must be optimized depending 
of the type of specimen to overcome the presence of PCR inhibitors (i.e., nasopharyngeal 
samples have higher rate of PCR inhibition than throat swabs). Differential sample 
preparation from the same specimen has been done when testing separate single-species 
PCRs on BAL [De Barbeyrac et al., 1993]. A culture-enhanced PCR approach has also been 
suggested to overcome the effect of inhibitors in the amplification process [Abele-Horne et 
al., 1998]. 
In early 2000s, Loens et al.(2003) stated that the development and application of new nucleic 
acid amplification techniques (NAATs) in diagnostic mycoplasmology required proper 
validation and standardization, and performance of different NAATs must be compared 
with each other in order to define the most sensitive and specific tests. The NAATs have 
demonstrated their potential to produce rapid, sensitive and specific results, and are now 
considered the methods of choice for direct detection of M. pneumoniae, M. genitalium, and 
M. fermentans [Cassell et al., 1994a]. There is a great variation in methods used from study to 
study, including variability of target gene sequences (P1, 16S RNA, ATPase, tuf), assay 
format (single, multiplex) or technologies (Real-time PCR, NASBA) [Loens et al., 2003a, 
2010]. Also, different specimens have been used, such as sputum, nasopharyngeal or 
pharyngeal swabs, brochoalveolar lavages or pleural fluid, and then it is difficult to compare 
these data. A comprehensive review about the use of NAATs for the detection of M. 
pneumoniae in clinical samples was done by Loens et al., 2003b, 2010, and by Ieven, 2010. 
Table 3, shows a selection of primers sets developed in the 1990s for testing diverse clinical 
samples.  
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Organism Primer sets Sequence    (5’3’) Target Amplicon 
size (bp) 
Ref. 
Mollicutes-
specífic  
FW: 
RV: 
GPO-1 
MGSO 
ACT CCT ACG GGA GGC AGC AGT A  
TGC ACC ATC TGT CAC TCT GTT AAC CTC 
rDNA 
16S 
715 
Van Kuppeveld 
et al., 1992 
M. 
fermentans 
FW: 
RV: 
IP:  
RW005 
RW004 
RW006 
GGT TAT TCG ATT TCT AAA TCG CCT 
GGA CTA TTG TCT AAA CAA TTT CCC 
GCT GTG GCC ATT CTC TTC TAC GTT 
IS-like 
element 
206 
Wang et al., 
1992 
FW: 
RV: 
IP:  
Mf-1 
Mf-2 
GPO-1 
GAA GCC TTT CTT CGC TGG AG 
ACA AAA TCA TTT CCT ATT CTG TC 
ACT CCT ACG GGA GGC AGC AGT A 
rDNA 
16s 
272 
Van Kuppeveld 
et al., 1992 
M. 
genitalium 
FW: 
RV: 
IP:  
MGS-1 
MGS-2 
MGS-I 
GAG CCT TTC TAA CCG CTG C 
GTG GGG TTG AAG GAT GAT TG 
AAG CAA CGT AGT AGC GTG AGC 
MgPa 
adhesio
n gene 
673 
De Barbeyrac et 
al., 1993 
FW: 
RV:  
IP:  
MGS-1 
MGS-4 
MGS-I 
GAG CCT TTC TAA CCG CTG C 
GTT GTT ATC ATA CCT TCT GAT 
AAG CAA CGT AGT AGC GTG AGC 
MgPa 
adhesio
n gene 
371 
De Barbeyrac et 
al., 1993 
M. hominis 
FW: 
RV:  
IP:  
MYCHOMP 
MYCHOMN 
MYCHOMS 
ATA CAT GCA TGT CGA GCG AG 
CAT CTT TTA GTG GCG CCT TAC 
CGC ATG GAA CCG CAT GGT TCC GTT G 
rDNA 
16s 
170 Grau et al., 1994 
FW: 
RV: 
IP:  
Mh-1 
Mh-2 
GPO-1 
TGA AAG GCG CTG TAA GGC GC 
GTC TGC AAT CAT TTC CTA TTG CAA A 
ACT CCT ACG GGA GGC AGC AGT A 
rDNA 
16s 
281b 
Van Kuppeveld 
et al., 1992 
M. 
penetrans 
FW: 
RV:  
IP:  
MYCPENETP 
MYCPENETN 
MYCPENETS 
CAT GCA AGT CGG ACG AAG CA 
AGC ATT TCC TCT TCT TAC AA 
CAT GAG AAA ATG TTT AAA GTC TGT TTG 
rDNA 
16s 
407 Grau et al., 1994 
M. 
pneumoniae 
FW: 
RV:  
IP:  
MP5-1 
MP5-2 
MP5-4 
GAA GCT TAT GGT ACA GGT TGG 
ATT ACC ATC CTT GTT GTA AGG 
CGT AAG CTA TCA GCT ACA TGG AGG 
Unknow
n gene 
144 
Bernet et al., 
1989 
FW: 
RV:  
IP:  
MP-P11 
MP-P12 
MP-I 
TGC CAT CAA CCC GCG CTT AAC 
CCT TTG CAA CTG CTC  ATA GTA 
CAA ACC GGG CAG ATC ACC TTT 
P1 
adhesin 
gene 
466 
De Barbeyrac et 
al., 1993 
Ureaplasma 
spp. 
FW: 
RV:  
IP:  
U5 
U4 
U9 
CAA TCT GCT CGT GAA GTA TTA C 
ACG ACG TCC ATA AGC AAC T 
GAG ATA ATG ATT ATA TGT CAG GAT CA 
Urease 
genes 
429 
Blanchard et al., 
1993 
FW: 
RV: 
IP:  
Uu-1 
Uu-2 
UUSO 
TAA ATG TCG GCT CGA ACG AG 
GCA GTA TCG CTA GAA AAG CAA C 
CAT CTA TTG CGA CGC TA 
rDNA 
16s 
311 
Van Kuppeveld 
et al., 1992 
U. parvum 
U. 
urealyticum 
FW: 
RV:  
UMS-125 
UMA-226- 
GTA TTT GCA ATC TTT ATA TGT TTT CG 
CAG CTG ATG TAA GTG CAG CAT TAA ATT C 
MBA 
gene 
402,403 
(Up) 
443 (Uu) 
Kong et al., 1999 
bp, Base pairs; FW, Forward; RV, Reverse; IP, Internal probe. 
Table 3. Selected primer sets used for detection of mycoplasmas in clinical specimens 
6. Treatment and prevention 
Due to absence of the cell wall envelope, mycoplasmas are insensitive to ǃ-lactam 
antibiotics. However, antibiotics targeting protein synthesis or DNA modification molecules 
are highly effective against these bacteria. Macrolides, tetracyclines and fluoroquinolones 
eliminate mycoplasmas efficiently both in vivo and in vitro [Cassell et al., 1994a; Waites et al., 
2000, 2008].  
Mycoplasmal infections in the upper respiratory tract are usually self-limiting, so antibiotic 
treatment is not generally recommended, even though some clinicians recommend it to 
prevent the risk of recurrence of respiratory illness [Waites & Talkington, 2004]  
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The antimicrobial of choice for treating lower respiratory tract M. pneumoniae infections are 
the macrolides in both adults and children. Patients receiving macrolides of recent 
generation showed improved tolerance, require fewer doses and have shorter treatment 
duration than older compounds. However, empirical antimicrobial treatment for M. 
pneumoniae-infected ambulatory patients is more practical; hence if hospitalization is 
required and/or patient has underlying risk factor, antimicrobial susceptibility testing is 
recommended. Use of tetracycline and fluoroquinolones is restricted to treat adult patients 
and should not be used in children aged <8 years [Cassell et al., 1994a; Waites et al., 2000]. A 
potential problem in the antimicrobial management of M. pneumoniae infections is the 
emergence of macrolide resistance [Atkinson et al., 2008; Waites et al., 2008]. 
The recovery of Ureaplasma spp and/or M. hominis in pure or mixed cultures from clinical 
specimens of symptomatic patients, in absence of associated biota, should be considered 
sufficient to initiate antimicrobial therapy. These microorganisms are resistant to 
sulfonamides and trimethoprim, and often exhibit resistance to aminoglycosides and 
chloramphenicol. Ureaplasma spp is resistant to clindamycin and susceptible to 
erythromycin, whereas M. hominis shows the opposite susceptibility profile. While 
tetracyclines are the antibiotics of choice for treating ureaplasmal infections in adults, 
erythromycin therapy is recommended for neonates. In contrast, M. hominis infections other 
than central nervous system in children under 8 years of age can be treated with 
clindamycin [Cassell et al., 1994a; Waites et al., 2000, 2005].  
Since strains from several mycoplasma species rapidly acquire resistance to antimicrobials, 
prevention of mycoplasmal infections via chemoprophylaxis is not recommended [Razin et 
al, 1998].  
6.1 Mycoplasmal susceptibility testing 
As antibiotic-resistant strains of mycoplasmas have appeared and become more common, 
antibiotic susceptibility testing for these microorganisms has become important. [Roberts, 
M.C., 1992]. However there are no official guidelines for performance, interpretation, or 
quality control of in vitro susceptibility tests for human mycoplasmas [Waites & Talkington, 
2004].  
The broth dilution method is the most widely used. Prior to test, pure cultures should be 
passage in appropriate broth and the color-changing units (CCU) or colony-forming units 
(CFU) quantitative method.  For the assay, bacterial cultures should be adjusted to 1000 – 
10000 CCU in 0.2 mL, followed by a 2-hour incubation at 37ºC, to begin active growth. The 
broth microdilution assay involves the addition of 100-μL aliquots of adjusted cultures to 
wells 2 – 12, then 100 μL of broth containing the highest concentration of the antibiotics is 
added to wells 1 and 2, followed by 2-fold serial dilutions up to well 12 (concentration range 
256-0.008 μg/mL). Positive and negative controls should be included.  The initial minimal 
inhibitory concentration (MIC) is defined as the lowest dilution of antibiotic in which 
metabolism of the organism is inhibited, as evidenced by lack of color change in the media 
at the time the control organism well first shows color change. Presumptive MICs for 
ureaplasmas will be available at 16 to 24 h and those for M. hominis will be at 36 to 48 h but 
M. pneumoniae may require 5 days or more until evidence of grow in the control wells is 
evident [Cassell et al., 1994a; Waites et al., 2000]. 
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There are commercial kits for mycoplasma susceptibility testing such as: Mycoplasma IST, 
Mycoplasma SIR, Mycofast “All In”, and MYCOKIT ATB, although they are available only 
in Europe.  
Reports of macrolide resistance in M. pneumoniae strains have been published since the past 
decade. These resistant strains were shown to possess gene mutations in the 23S rRNA.  The 
impact of macrolide resistance on the clinical course of infections is still unclear, but PCR 
assays have been developed to detect some of these mutations in order to identify these 
resistant strains [Atkinson et al., 2008]. 
Tetracycline resistance among Ureaplasma spp and M. hominis  isolates can be distinguished 
by broth- or agar-based methods since the resistant strains consistently have MICs of ≥ 8 
μg/mL whereas susceptible strains have MICs of ≤ 2 μg/mL, with no overlapping between 
the two populations [Waites et al., 2000; Cassell et al., 1994a]. Tetracycline resistance among 
M. hominis and Ureaplasma spp. isolates has been associated with the presence of Tet M 
determinant which codes for production of a ribosome-binding protein that prevents 
tetracycline binding to ribosomes [Roberts, M.C., 2002].  
6.2 Vaccines  
The initial vaccine candidate for M. pneumoniae was formalin-inactivated bacteria, but their 
protective efficacy results were generally disappointing, since some immunized volunteers 
developed more severe illness after experimental challenge with live mycoplasmas. 
Development of live attenuated vaccines never made it to human use due to concern over 
residual virulence of the vaccine strain of M. pneumoniae [Waites et al., 2008]. Other vaccine 
candidates have included acellular protein and polysaccharide components and 
recombinant DNA. While the importance of the P1 adhesin in mediating M. pneumoniae 
cytadherence and initiation of disease cannot be denied, animal studies using P1 as a 
vaccine antigen have not demonstrated protective efficacy [Razin et al., 1998; Waites & 
Talkington, 2004].  
As higher rates of surface antigenic variation among several human mycoplasmas have been 
described, whenever promising antigens are selected as vaccine candidates they are rapidly 
discarded. The three types of antigenic variation are: 1) Phase variation, a feature involving 
selective turning on/off of gene transcription; 2) Size variation as a result of variation in the 
number of tandem repeats near the 5’ end; and 3) Differential masking of surface antigens 
by the lipid moiety of lipoproteins [Chambaud et al., 1999; Momynaliev & Govorun, 2001].  
The availability of the full genome sequences of several human mycoplasmas, will allow 
better understanding of the structure and functionality of these bacteria, including virulence 
factors and immunogenic molecules.  
7. Concluding remarks 
It is undeniable the ability of Mycoplasma pneumoniae and Ureaplasma spp. to cause 
pneumonia. Other mycoplasma species are potential respiratory pathogens, especially in 
conjunction with immune compromise. There is strong evidence that mycoplasmal 
respiratory infections elicit inflammatory responses that can result chronic lung injury both 
in adults and neonates. Improvement of laboratory methods for research and diagnostic 
purposes in mycoplasmology has allowed establishing associations with pulmonary 
diseases such as COPD, asthma, and BPD. However additional work must be done for 
prevention, treatment strategies and vaccine development. 
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